IDBI Healthcare Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

IDBI Healthcare Growth Direct Plan

NAV
₹31.4658
+0.21%
(17 Jan)
AUM
86 Cr
TER
1.22%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+34.3%
+20.2%
+18.4%
+18.2%
+7.6%
3Y
+16.6%
+29.9%
+31.8%
+29.8%
+30.0%
5Y
+23.2%
+28.7%
+24.1%
+26.3%
+26.9%
ALL
+21.5%
+17.5%
+11.9%
+16.9%
+26.7%
VOL
15.9%
18.1%
20.3%
19.7%
22.7%
TER
1.2%
1.2%
0.8%
0.8%
0.5%
AUM
₹86 Cr
₹6,911 Cr
₹4,572 Cr
₹1,286 Cr
₹5,237 Cr
INFO
1.35
0.96
0.58
0.86
1.18
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
IDBI Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Dec
Top holdings
Sun Pharmaceuticals Industries Ltd
10.5%
Piramal Pharma Ltd
7.0%
Artemis Medicare Services Ltd Ordinary Shares
6.2%
Torrent Pharmaceuticals Ltd
5.3%
Glenmark Pharmaceuticals Ltd
4.6%
Mankind Pharma Ltd
4.5%
Cipla Ltd
4.3%
Ipca Laboratories Ltd
4.2%
J.B. Chemicals & Pharmaceuticals Ltd
4.1%
Abbott India Ltd
4.1%
Top industry exposure
Healthcare
90.0%
Basic Materials
3.6%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
37%
Lock-in period
-
Exit load
• 1% for redemption within 90 days
Fund objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Fund manager(s)
Karan Doshi

FAQs